MedTrace Logo

A Clinical Trial of Lurasidone in Treatment of Schizophrenia

NCT02002832 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 388

Last updated 2019-11-15

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.

Conditions

Interventions

DRUG

Lurasidone tablets

Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)

DRUG

Risperidone tablets

Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)

Sponsors & Collaborators

  • Sumitomo Pharma (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhuoji CAI, MD · Capital Medical University Affiliated Beijing Anding Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-04-30
Completion
2015-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02002832 on ClinicalTrials.gov